Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI). Authors: ...

The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...

Background: Combining immune checkpoint inhibitor (ICI) with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types. This phase II ...

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers. They reported data to support this conclusion in the European Journal of ...

New trial results show that pembrolizumab given both before and after surgery for stage 2B-3 melanoma improved event-free survival compared with adjuvant therapy alone.